All posts by medical

Biochemistry

Postdoc position in time-resolved crystallography (1.0 FTE) (220213) – Nature.com

Job descriptionWe are looking for a postdoctoral fellow with backgrounds in crystallography or related fields who are motivated to work in an interdisciplinary research environment studying the dynamics of membrane transporters using the combination of photopharmacology and time-resolved crystallography. This research project is financially supported by the Dutch Science Foundation.In this project, the membrane protein dynamics during a ligand binding will be assessed both on millisecond (using synchrotron radiation) and femtosecond scale (using XFELs). Biochemistry and crystallisation protocols are in place. The nature of the project requires considerable travelling for data collection at synchrotron facilities.The postdoctoral fellow will become a member of the research group led by Dr. Albert Guskov, which is embedded in the GBB research Institute. The fellow will have access to cutting-edge structural biology facilities, both in-house (crystallisation and optimisation robots, imager, etc.) as well as access to top research facilities such as ESRF, Petra III, Eu-XFEL and PAL for measurements.Postdoctoral fellows can receive training and advanced courses or workshops on generic research, transferable skills and teaching. Postdoctoral fellows at the Faculty of Science and Engineering also benefit from a Postdoc community to meet peers.As a postdoctoral fellow, you are committed to conduct independent and original scientific research, to report on this research in international publications and presentations. Postdoctoral fellows are expected to contribute about 10% of their overall workload to teaching.QualificationsThe candidates should have the following qualifications: a PhD degree with specialisation in structural biology, biochemistry, chemistry, biophysics, or related field is required excellent communication and writing skills in English ability to work independently and in a team proven experience in membrane protein production, purification and crystallisation experience in macromolecular crystallography experience in serial crystallography (data collection, data processing) is an advantage.OrganisationFounded in 1614, the University of Groningen enjoys an international reputation as a dynamic and innovative centre of higher education offering high-quality teaching and research. Flexible study programmes and academic career opportunities in a wide variety of disciplines encourage the 32,000 students and researchers alike to develop their own individual talents. As one of the best research universities in Europe, the University of Groningen has joined forces with other top universities and networks worldwide to become a truly global centre of knowledge.The Groningen Biomolecular Sciences and Biotechnology Institute (GBB), one of the larger institutes of the Faculty of Science and Engineering (FSE), provides an excellent environment for top-notch research in the field of biomolecular sciences. Twelve vibrant research groups with strong roots in biochemistry, biophysical chemistry, cell biology, computational biology, genetics, microbiology, molecular biology, and systems biology are organised in two focal areas: Molecular Mechanisms of Biological Processes and Physiology and Systems Biology.Conditions of employmentWe offer you in accordance with the Collective Labour Agreement for Dutch Universities: a salary based on qualifications and experience, starting at 3,353 gross per month (salary scale 10), based on a fulltime position (1.0 FTE) a holiday allowance of 8% an 8.3% year-end bonus.The position offered is for 3 years. Each successful candidate will first be offered a temporary position of one year with the option of renewal for another 2 years. Prolongation of the contract is contingent on sufficient progress in the first year.The starting date is flexible.ApplicationYou may apply for this position until 15 July (23:59 h) / before 16 July 2020 (00:00h) 2020 Dutch local time by means of the online application form (click on Apply below on the advertisement on the university website).Applications for the position should include (as a single PDF file): cover letter with background and motivation to apply for this position curriculum vitae, including details of your PhD degree and the publication list contact details of 2-3 academic references, including your PhD supervisor.Interviews are scheduled to take place in July & August 2020. The envisaged starting date is 1 September 2020, but is negotiable.We are an equal opportunity employer and value diversity at our University. We are committed to building a diverse faculty so you are encouraged to apply. Our selection procedure follows the guidelines of the Recruitment code (NVP), http://nvp-plaza.nl/download/?id=7714 and European Commissions European Code of Conduct for recruitment of researchers, https://euraxess.ec.europa.eu/jobs/charter/codeUnsolicited marketing is not appreciated.InformationFor information you can contact:Dr. Albert Guskov, a.guskov@rug.nlPlease do not use the e-mail address(es) above for applications.Additional informationGroningen Biomolecular Science and Biotechnology InstituteCurrent research group and output of Dr. Albert Guskov 1/2Current research group and output of Dr. Albert Guskov 2/2

Read more:
Postdoc position in time-resolved crystallography (1.0 FTE) (220213) - Nature.com

Biochemistry

Biochemical Diagnostic Reagent Market | Covid-19 Impact | Demand, Cost Structures, Latest trends, and Forecasts to 2024 | Key Players: Roche, Siemens…

Biochemical Diagnostic Reagent Market with Covid-19 Impact Analysis: Forecast to Show Spurring Growth by 2020-2024 to its research database. The global Biochemical Diagnostic Reagent Market research report is an output of a brief assessment and an extensive analysis of practical data collected from the global Biochemical Diagnostic Reagent market. The data are collected on the basis of industrial drifts and demands related to the services & products. The meticulously collected data offers for the process of effortless strategic planning. It also helps in creating promising business alternatives.

Free Sample Report + All Related Graphs & Charts @ https://www.acquiremarketresearch.com/sample-request/362392/

A perfect demonstration of the recent expansions and innovative technological resolutions offer our customers the liberty to develop their decision-making skills. This ultimately helps to work with perfect business alternatives and apply elegant implementations. The global Biochemical Diagnostic Reagent Market report emphasizes the latest developments, growth, new opportunities, and dormant tricks. It provides an all-inclusive stance of the global Biochemical Diagnostic Reagent Market. Requirement proportion and innovation of modern technologies are some of the key factors covered in the global Biochemical Diagnostic Reagent Market report.

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

This helps to understand the overall market and to recognize the growth opportunities in the global Biochemical Diagnostic Reagent Market. The report also includes a detailed profile and information of all the major market players currently active in the global Biochemical Diagnostic Reagent Market. The companies covered in the report can be evaluated on the basis of their latest developments, financial and business overview, product portfolio, key trends in the market, long-term and short-term business strategies by the companies in order to stay competitive in the market.

Download Free PDF Report Brochure @ https://www.acquiremarketresearch.com/sample-request/362392/

Some of the Major Market Player Profile Included in This Report is:

Roche, Siemens Healthineers, Beckman Coulter, Randox, BioSino, Beijing Leadman Biochemistry, FosunPharma, Beijing Strong Biotechnologies, Dojindo Laboratories, Sysmex, KAINOS Laboratories, DAAN Gene

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Liquid Double Reagent, Dry Powder Double Reagent .

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Hospital, Clinic, Laboratory.

The greater part of the data gathered is presented in graphical form along with the related statistics. The global Biochemical Diagnostic Reagent Market report demonstrates the functioning of the main market players, suppliers, and dealers in detail. The report also highlights the restraints and drivers impacting the global Biochemical Diagnostic Reagent Market.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The report analyzes various decisive constraints such as item price, production capability, profit & loss statistics, and transportation & delivery channels influencing the global Biochemical Diagnostic Reagent Market. It also covers the analysis of other important elements such as market demands, advancements, and product developments, various organizations, and processes impacting the global Biochemical Diagnostic Reagent Market. The global Biochemical Diagnostic Reagent Market research report emphasizes a variety of modifications done that improve the work process of the global Biochemical Diagnostic Reagent Market.

Grab Your Report at an Impressive Discount (Use Corporate email ID to Get Higher Priority) @ https://www.acquiremarketresearch.com/discount-request/362392/

A methodically structured Biochemical Diagnostic Reagent Market research report is based on the primary and secondary resource. It portrays the data collected in a more communicative and expressive way allowing the customer to develop a well-structured plan to develop and expand their businesses in the estimated duration.

Promising Regions & Countries Mentioned in The Biochemical Diagnostic Reagent Market Report:

North America: United States, Canada, and Mexico.South & Central America: Argentina, Chile, and Brazil.Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa.Europe: UK, France, Italy, Germany, Spain, and Russia.Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Buy Full Copy Global Biochemical Diagnostic Reagent Report 2020-2024 @ https://www.acquiremarketresearch.com/buy-now/362392/?price=su

COVID-19- Current Scenario & Potential Impact

Various communities and companies are doing their best to function and perform, and eventually cope with the challenges raised by COVID-19 pandemic. The COVID-19 pandemic had a negative impact on the market size for the year 2020, with small and medium scale companies struggling to sustain their businesses in the near-term future. Industry leaders are now focusing to create new business practices to deal with crisis situations like COVID-19 pandemic.

The report presents a strategic analysis of the Biochemical Diagnostic Reagent market through key drivers, challenges, opportunities, and growth contributors. Further, the market attractiveness index is provided based on five forces analysis.

The Biochemical Diagnostic Reagent market delivers value to customers through reliable market size for 2019 on the basis of demand and price analysis. The report presents near term and long term forecast of the addressable Biochemical Diagnostic Reagent market size to 2024.

(We customize your report according to your research need. Ask our sales team for report customization. [emailprotected])

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About us:

Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Go here to see the original:
Biochemical Diagnostic Reagent Market | Covid-19 Impact | Demand, Cost Structures, Latest trends, and Forecasts to 2024 | Key Players: Roche, Siemens...

Biochemistry

SINTX Technologies Announces Publication of Study to Reduce the Spread and Transfer of Coronavirus – Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--SINTX Technologies, Inc. (NASDAQ: SINT) (SINTX or the Company), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride and its applications, today announced positive testing results demonstrating the anti-viral properties of its silicon nitride which may be useful in the reduction of the spread of COVID-19. The study results demonstrated that SINTXs unique grade of silicon nitride inactivates the SARS-CoV-2 virus within a minute after exposure, and has the potential to decrease the risk of viral disease spread on surfaces.

Studies have shown that coronavirus spreads between humans when an infected person coughs or sneezes. Also, the virus can remain active on a variety of commonly touched surfaces for hours to days. SINTX believes that by incorporating its unique composition of silicon nitride into products such as face masks, and personal protective equipment, it is possible to manufacture surfaces that inactivate viral particles, thereby limiting the spread of the disease. SINTX envisions incorporating its silicon nitride into high-contact surfaces such as medical equipment, screens, countertops, and doorknobs in locations where viral persistence is a concern, such as homes, casinos, and cruise ships.

The study builds upon years of research toward understanding the basic biochemistry of silicon nitride, said Dr. Sonny Bal, President, and CEO of SINTX. The antiviral attributes of silicon nitride are consistent with the known antibacterial behavior of silicon nitride. The results with coronavirus inactivation are likewise consistent with an earlier study that showed similar inactivation of other viruses, including Influenza A and Enterovirus, both of which cause human disease.

The study and testing results show promise toward developing a new category of face masks for healthcare professionals and general consumers, said Bruce Lorange, Founder, and CEO, O2TODAY. Face masks used by healthcare workers today can capture virus particles, but the virus can remain viable in the mask, even as long 7 days after use. Inclusion of silicon nitride technology into the mask may enhance personal safety while reducing the risk of disease spread.

This antiviral discovery opens many new opportunities for SINTX. In composites, coatings, and mixtures, silicon nitride has maintained its antibacterial and osteogenic properties, even at small fractions. We believe that incorporating our material into a variety of commonly-touched surfaces will discourage viral spread, and contribute to global health by reducing the risk of disease, Dr. Bal added.

The present study was done independently, with SINTX supplying its silicon nitride for the testing. The complete data and study can be downloaded at bioRxiv. Additional tests are underway at several U.S. research centers to further understand the isolation and optimization of the antiviral properties of silicon nitride; those results will be shared as they become available.

About SINTX Technologies, Inc.

SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company manufactures silicon nitride material and components in its FDA registered and ISO 13485 certified facility. For more information on SINTX Technologies or its silicon nitride material platform, please visit http://www.sintx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (PSLRA) that are subject to several risks and uncertainties. Risks and uncertainties that may cause such differences to include, among other things, that SINTX has not developed any PPE products which incorporate the use of silicon nitride, incorporation of silicon nitride into PPE may not be safe or effective; the uncertainties inherent in research and development, including the cost and time required to advance our products to regulatory submission; market acceptance of our products once cleared and commercialized; our ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect managements current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTXs Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTXs other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Read this article:
SINTX Technologies Announces Publication of Study to Reduce the Spread and Transfer of Coronavirus - Business Wire

Biochemistry

citybizlist : Washington DC : Replicate Bioscience and Immunomic Therapeutics Form Collaboration – Citybizlist Real Estate

ROCKVILLE, Md. & SAN DIEGO--(BUSINESS WIRE)--Replicate Bioscience, Inc., a privately-held biopharmaceutical company creating novel treatments to prevent drug resistance in cancers, and Immunomic Therapeutics, Inc., a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that the companies have entered into a research and licensing option agreement to combine their platform technologies to combat infectious diseases and cancers.

ITI and Replicate will develop candidates combining ITIs UNITE technology with Replicates scalable self-replicating RNA (SynRGY technology) for COVID-19, HPV, and EBV. Through the collaboration, ITI will be responsible for all development costs and ITI will also invest in Replicate Bioscience. As part of the investment, ITIs Co-founder and Chief Scientific Officer, Dr. Teri Heiland, will be appointed to Replicates Scientific Advisory Board.

We are excited to partner with Replicate and invest in their seed round as the first strategic shareholder of the company. They have an impressive team with a wealth of expertise in RNA therapeutics and immuno-oncology and we believe that their SynRGY technology is a next-generation solution for combatting drug resistance in cancer, said Dr. William Hearl, CEO of Immunomic Therapeutics. Through this collaboration, we look forward to combining SynRGY with our UNITE platform in infectious disease development programs, including those useful in cancers.

Ninety-percent of cancer related deaths are a direct result of drug resistance caused by the evolution of the tumor over time. Developing treatments for drug resistance that are deployable at earlier stages of care is a critical unmet need. Alongside their investment, the Immunomic Therapeutics team brings immense value in supporting the development of our internal wholly-owned immuno-oncology candidates. In addition, their team is ideally suited to clinically advancing our joint candidates, said Dr. Nathaniel Wang, CEO of Replicate Bioscience. Through this partnership, we are excited to rapidly advance candidates into the clinic for COVID-19 and infectious diseases that lead to the development and progression of various cancers.

About UNITE

ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics. The Company has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit http://www.immunomix.com.

About Replicate Bioscience

Replicate Bioscience, Inc. (Replicate) is a privately-held clinical stage biopharmaceutical company focused on creating novel oncology treatments to prevent drug resistance. By deploying its SynRGY technology, Replicate aims to create solutions that enhance the effectiveness of many immuno-oncology regimens in early stages of care. Replicate is a Duke University spinout of tumor resistance-targeting technology from faculty members H. Kim Lyerly and Zachary Hartman and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate aims to maximize the potential of its SynRGY platform through partnerships in infectious diseases. Replicate has entered into strategic collaborations with Immunomic Therapeutics and Duke University. Replicate maintains its headquarters in San Diego, CA as part of the BioLab community of companies. For more information, please visit http://www.replicatebioscience.com.

Here is the original post:
citybizlist : Washington DC : Replicate Bioscience and Immunomic Therapeutics Form Collaboration - Citybizlist Real Estate

Biochemistry

Domperidone Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 – Farmers Ledger

LOS ANGELES, United States: The report is an all-inclusive research study of the global Domperidone market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Domperidone market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Domperidone report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)

https://www.qyresearch.com/sample-form/form/1453495/global-domperidone-market

In addition, market revenues based on region and country are provided in the Domperidone report. The authors of the report have also shed light on the common business tactics adopted by players. The leading players of the global Domperidone market and their complete profiles are included in the report. Besides that, investment opportunities, recommendations, and trends that are trending at present in the global Domperidone market are mapped by the report. With the help of this report, the key players of the global Domperidone market will be able to make sound decisions and plan their strategies accordingly to stay ahead of the curve.

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Domperidone market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Domperidone market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

Key Players Mentioned in the Global Domperidone Market Research Report: Schwitz Biotech, Luckys Pharma, Shreeji Pharma International, Xian Janssen Pharmaceutical, Hunan Qianjin Xiangjiang, Foshan Shouxin Pharmaceutical, Jiangxi Jiezhong Biochemistry, Meenaxy Pharma Pvt. Ltd, Hainan Asia Pharmaceutical, Lizhu Pharmaceutical Group, Jiangxi Huiren Pharmaceutical

Global Domperidone Market Segmentation by Product: , Tablets, Pellets, Other

Global Domperidone Market Segmentation by Application: , Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Key Players: The Key manufacturers that are operating in the

The Domperidone Market report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Domperidone market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Domperidone market and its potential to grow in the years to come.

Key questions answered in the report:

Request for customization in Report: https://www.qyresearch.com/customize-request/form/1453495/global-domperidone-market

Table of Content

Table of Contents 1 Domperidone Market Overview1.1 Product Overview and Scope of Domperidone1.2 Domperidone Segment by Type1.2.1 Global Domperidone Sales Growth Rate Comparison by Type (2021-2026)1.2.2 Tablets1.2.3 Pellets1.2.4 Other1.3 Domperidone Segment by Application1.3.1 Domperidone Sales Comparison by Application: 2020 VS 20261.3.2 Hospital Pharmacies1.3.3 Retail Pharmacies1.3.4 Online Pharmacies1.4 Global Domperidone Market Size Estimates and Forecasts1.4.1 Global Domperidone Revenue 2015-20261.4.2 Global Domperidone Sales 2015-20261.4.3 Domperidone Market Size by Region: 2020 Versus 2026 2 Global Domperidone Market Competition by Manufacturers2.1 Global Domperidone Sales Market Share by Manufacturers (2015-2020)2.2 Global Domperidone Revenue Share by Manufacturers (2015-2020)2.3 Global Domperidone Average Price by Manufacturers (2015-2020)2.4 Manufacturers Domperidone Manufacturing Sites, Area Served, Product Type2.5 Domperidone Market Competitive Situation and Trends2.5.1 Domperidone Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key Domperidone Players (Opinion Leaders) 3 Domperidone Retrospective Market Scenario by Region3.1 Global Domperidone Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global Domperidone Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America Domperidone Market Facts & Figures by Country3.3.1 North America Domperidone Sales by Country3.3.2 North America Domperidone Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe Domperidone Market Facts & Figures by Country3.4.1 Europe Domperidone Sales by Country3.4.2 Europe Domperidone Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific Domperidone Market Facts & Figures by Region3.5.1 Asia Pacific Domperidone Sales by Region3.5.2 Asia Pacific Domperidone Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America Domperidone Market Facts & Figures by Country3.6.1 Latin America Domperidone Sales by Country3.6.2 Latin America Domperidone Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa Domperidone Market Facts & Figures by Country3.7.1 Middle East and Africa Domperidone Sales by Country3.7.2 Middle East and Africa Domperidone Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global Domperidone Historic Market Analysis by Type4.1 Global Domperidone Sales Market Share by Type (2015-2020)4.2 Global Domperidone Revenue Market Share by Type (2015-2020)4.3 Global Domperidone Price Market Share by Type (2015-2020)4.4 Global Domperidone Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Domperidone Historic Market Analysis by Application5.1 Global Domperidone Sales Market Share by Application (2015-2020)5.2 Global Domperidone Revenue Market Share by Application (2015-2020)5.3 Global Domperidone Price by Application (2015-2020) 6 Company Profiles and Key Figures in Domperidone Business6.1 Schwitz Biotech6.1.1 Corporation Information6.1.2 Schwitz Biotech Description, Business Overview and Total Revenue6.1.3 Schwitz Biotech Domperidone Sales, Revenue and Gross Margin (2015-2020)6.1.4 Schwitz Biotech Products Offered6.1.5 Schwitz Biotech Recent Development6.2 Luckys Pharma6.2.1 Luckys Pharma Domperidone Production Sites and Area Served6.2.2 Luckys Pharma Description, Business Overview and Total Revenue6.2.3 Luckys Pharma Domperidone Sales, Revenue and Gross Margin (2015-2020)6.2.4 Luckys Pharma Products Offered6.2.5 Luckys Pharma Recent Development6.3 Shreeji Pharma International6.3.1 Shreeji Pharma International Domperidone Production Sites and Area Served6.3.2 Shreeji Pharma International Description, Business Overview and Total Revenue6.3.3 Shreeji Pharma International Domperidone Sales, Revenue and Gross Margin (2015-2020)6.3.4 Shreeji Pharma International Products Offered6.3.5 Shreeji Pharma International Recent Development6.4 Xian Janssen Pharmaceutical6.4.1 Xian Janssen Pharmaceutical Domperidone Production Sites and Area Served6.4.2 Xian Janssen Pharmaceutical Description, Business Overview and Total Revenue6.4.3 Xian Janssen Pharmaceutical Domperidone Sales, Revenue and Gross Margin (2015-2020)6.4.4 Xian Janssen Pharmaceutical Products Offered6.4.5 Xian Janssen Pharmaceutical Recent Development6.5 Hunan Qianjin Xiangjiang6.5.1 Hunan Qianjin Xiangjiang Domperidone Production Sites and Area Served6.5.2 Hunan Qianjin Xiangjiang Description, Business Overview and Total Revenue6.5.3 Hunan Qianjin Xiangjiang Domperidone Sales, Revenue and Gross Margin (2015-2020)6.5.4 Hunan Qianjin Xiangjiang Products Offered6.5.5 Hunan Qianjin Xiangjiang Recent Development6.6 Foshan Shouxin Pharmaceutical6.6.1 Foshan Shouxin Pharmaceutical Domperidone Production Sites and Area Served6.6.2 Foshan Shouxin Pharmaceutical Description, Business Overview and Total Revenue6.6.3 Foshan Shouxin Pharmaceutical Domperidone Sales, Revenue and Gross Margin (2015-2020)6.6.4 Foshan Shouxin Pharmaceutical Products Offered6.6.5 Foshan Shouxin Pharmaceutical Recent Development6.7 Jiangxi Jiezhong Biochemistry6.6.1 Jiangxi Jiezhong Biochemistry Domperidone Production Sites and Area Served6.6.2 Jiangxi Jiezhong Biochemistry Description, Business Overview and Total Revenue6.6.3 Jiangxi Jiezhong Biochemistry Domperidone Sales, Revenue and Gross Margin (2015-2020)6.4.4 Jiangxi Jiezhong Biochemistry Products Offered6.7.5 Jiangxi Jiezhong Biochemistry Recent Development6.8 Meenaxy Pharma Pvt. Ltd6.8.1 Meenaxy Pharma Pvt. Ltd Domperidone Production Sites and Area Served6.8.2 Meenaxy Pharma Pvt. Ltd Description, Business Overview and Total Revenue6.8.3 Meenaxy Pharma Pvt. Ltd Domperidone Sales, Revenue and Gross Margin (2015-2020)6.8.4 Meenaxy Pharma Pvt. Ltd Products Offered6.8.5 Meenaxy Pharma Pvt. Ltd Recent Development6.9 Hainan Asia Pharmaceutical6.9.1 Hainan Asia Pharmaceutical Domperidone Production Sites and Area Served6.9.2 Hainan Asia Pharmaceutical Description, Business Overview and Total Revenue6.9.3 Hainan Asia Pharmaceutical Domperidone Sales, Revenue and Gross Margin (2015-2020)6.9.4 Hainan Asia Pharmaceutical Products Offered6.9.5 Hainan Asia Pharmaceutical Recent Development6.10 Lizhu Pharmaceutical Group6.10.1 Lizhu Pharmaceutical Group Domperidone Production Sites and Area Served6.10.2 Lizhu Pharmaceutical Group Description, Business Overview and Total Revenue6.10.3 Lizhu Pharmaceutical Group Domperidone Sales, Revenue and Gross Margin (2015-2020)6.10.4 Lizhu Pharmaceutical Group Products Offered6.10.5 Lizhu Pharmaceutical Group Recent Development6.11 Jiangxi Huiren Pharmaceutical6.11.1 Jiangxi Huiren Pharmaceutical Domperidone Production Sites and Area Served6.11.2 Jiangxi Huiren Pharmaceutical Domperidone Description, Business Overview and Total Revenue6.11.3 Jiangxi Huiren Pharmaceutical Domperidone Sales, Revenue and Gross Margin (2015-2020)6.11.4 Jiangxi Huiren Pharmaceutical Products Offered6.11.5 Jiangxi Huiren Pharmaceutical Recent Development 7 Domperidone Manufacturing Cost Analysis7.1 Domperidone Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of Domperidone7.4 Domperidone Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 Domperidone Distributors List8.3 Domperidone Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global Domperidone Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of Domperidone by Type (2021-2026)10.1.2 Global Forecasted Revenue of Domperidone by Type (2021-2026)10.2 Domperidone Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of Domperidone by Application (2021-2026)10.2.2 Global Forecasted Revenue of Domperidone by Application (2021-2026)10.3 Domperidone Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of Domperidone by Region (2021-2026)10.3.2 Global Forecasted Revenue of Domperidone by Region (2021-2026)10.4 North America Domperidone Estimates and Projections (2021-2026)10.5 Europe Domperidone Estimates and Projections (2021-2026)10.6 Asia Pacific Domperidone Estimates and Projections (2021-2026)10.7 Latin America Domperidone Estimates and Projections (2021-2026)10.8 Middle East and Africa Domperidone Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Excerpt from:
Domperidone Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Farmers Ledger

Cell Biology

Berkeley Lights Announces Opto(TM) Antigen-Presenting Bead Kit to Accelerate the Expansion of Antigen-Specific T Cells Used to Develop Cell-Based…

EMERYVILLE, Calif., June 24, 2020 /PRNewswire/ --Berkeley Lights, Inc., a leader in Digital Cell Biology, today announced the Opto Antigen-Presenting Bead (APB) kit, a new reagent kit that activates and expands antigen-specific T cells in peripheral blood to create artificial T cells. The APB kit is ten times more effective than the current, standard dendritic cell process, which is used for antigen discovery for cancer vaccines, TCR discovery for transgenic TCR cell therapy, and expansion of antigen-specific T cells for endogenous T cell therapy.

The APB kit is a part of the company's Opto Cell Therapy Development 2.0 workflow and with this new kit, scientists can measure multiple cytokines, visualize tumor cell killing,andexpand & validate rare T cells on the Beacon and Lightning systems. The functional properties of the resulting T cells are assayed and recovered for TCR or genome sequencing.

"T cell-based therapies are showing great promise for cancer treatment," said John Proctor, Ph.D., Senior Vice President of Marketing at Berkeley Lights. "Our APB kit will provide scientists developing these therapies with a way to rapidly identify existing T cells that will react to tumor antigens and expand them to generate enough antigen-specific T cells for use in TCR discovery and production of T cell therapies. Ultimately, we believe the APB kit will enable scientists to move to the next step of developing T cell-based therapies more quickly and efficiently."

The APB kit allows scientists to load any peptide onto a bead and measure critical peptide-Human Leukocyte Antigen (HLA) interactions before stimulating antigen-specific T cells with the best peptides. This new workflow removes the need to assay ineffective peptides that do not bind to the HLA complex in the first place. The APB kit consists of beads coated with co-stimulatory antibodies, an HLA complex that measures the degree of loading and stability of the peptide, and tetramers that stain the antigen-specific T cells that are generated. By replacing the role of dendritic cells in T cell workflows, this kit enables Berkeley Lights' customers to save time and costs by removing variability in antigen presentation.

The Opto Antigen-Presenting Bead (APB) kit will be available in early Fall 2020. More information can be found here: http://www.berkeleylights.com. Berkeley Lights' Beacon and Lightning systems and Culture Station instrument are for research use only. Not for use in diagnostic procedures.

About Berkeley LightsBerkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprised of proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain. Our mission is to accelerate the use of cell-based products by providing researchers access to the Berkeley Lights Platform to find the best cells in a fraction of the time and at a fraction of the cost of traditional methods.

Original post:
Berkeley Lights Announces Opto(TM) Antigen-Presenting Bead Kit to Accelerate the Expansion of Antigen-Specific T Cells Used to Develop Cell-Based...

Cell Biology

Biologists Unravel Tangled Mystery of Plant Cell Growth Insight Could Lead to Bigger Crops and Better Yields – SciTechDaily

When cells dont divide into proper copies of themselves, living things fail to grow as they should. For the first time, scientists now understand how a protein called TANGLED1 can lead to accurate cell division in plants.

Inside cells are structures called microtubules, which act like highways for moving proteins and organelles. Theyre also critical for separating DNA after it has been duplicated to eventually make two cells from one.

You cant live without microtubules, and plants cant either, said Carolyn Rasmussen, an assistant professor of plant cell biology at UC Riveride. Because theyre so important, where they go and how they move has to be carefully controlled.

Scanning electron micrographs of maize plant cells. Wild-type (left), and the TANGLED1 mutant (RIGHT). Credit: Carolyn Rasmussen/UCR

Rasmussen and colleagues discovered that the TANGLED1 protein performs this microtubule controlling function by binding the microtubules together like glue. Their description of how TANGLED1 operates was published today (June 22, 2020) in the Journal of Cell Biology.

By adding together microtubules and TANGLED1 in a test tube, the team saw surprising interactions between them. Often, proteins can only bundle microtubules at very specific angles 40 degrees or less. TANGLED1 can grab microtubules from any angle and link them together.

To the best of my knowledge, this is the first plant protein observed in vitro with this characteristic, Rasmussen said.

The proteins ability to capture and stabilize microtubules is likely critical for being able to separate daughter cells properly. Cell divisions at the wrong angle lead to big problems such as the formation of tumors.

Animal cells normally need to remain attached to a surface, and their division is controlled to ensure the cells remain there. If a cell becomes unattached to the surface after division, that could mark the beginning of a tumor.

Rasmussens team included Pablo Martinez, Sean OLeary, and Antonia Zhang from UC Riverside; biochemists Ram Dixit and Rachappa Balkunde from Washington University; and mathematician Kenneth Brakke from Susquehanna University.

Now that the team has seen TANGLED1 at work in vitro, the next step is to observe it in a living cell. If they can gain a deeper understanding of the genes that control plant cell division, these genes might be manipulated to produce higher yield crops, such as bigger ears of corn or more grain.

An additional benefit of this research is the insight it could yield into human cellular processes. When there are defects in the cells ability to move material around on microtubules, diseases such as Alzheimers disease or cancer could follow.

Research on these diseases is often conducted on human cell lines or animal models. However, there are similarities between the microtubule bundling behavior of TANGLED1 in plants and microtubule binding proteins in humans, making it easier to learn more by characterizing both at the same time.

People say plants dont get cancer, which is generally true, Rasmussen said. But sometimes when you have a different perspective on a related question in this case, what controls the spatial positioning of cell division you can see things that are hard to see in other model systems.

Reference: TANGLED1 mediates microtubule interactions that may promote division plane positioning in maize by Pablo Martinez, Ram Dixit, Rachappa S. Balkunde, Antonia Zhang, Sen E. OLeary, Kenneth A. Brakke and Carolyn G. Rasmussen, 22 June 2020, Journal of Cell Biology.DOI: 10.1083/jcb.201907184

More:
Biologists Unravel Tangled Mystery of Plant Cell Growth Insight Could Lead to Bigger Crops and Better Yields - SciTechDaily

Cell Biology

Neurons thrive even when malnourished – Newswise

Newswise ITHACA, N.Y. When animal, insect or human embryos grow in a malnourished environment, their developing nervous systems get first pick of any available nutrients so that new neurons can be made.

In this process, called organ sparing, resources are preferentially delegated to the nervous system at the cost of less important organs or tissues.

New research now shows that developing nervous systems demonstrate this preferential growth even at the level of individual neurons. In a paper published in eLife June 22,Low FoxO expression in Drosophila somatosensory neurons protects dendrite growth under nutrient restriction,a team of Cornell researchers discovered the molecular mechanism that helps facilitate organ sparing on this cell-by-cell basis.

The phenomena we found is similar to the phenomena of the sparing of the brain, but there are very important differences, saidChun Han, senior author and a Nancy M. and Samuel C. Fleming Associate Professor in the Department of Molecular Biology and Genetics in the College of Agriculture and Life Sciences and in the Weill Institute for Cell and Molecular Biology. The neurons are protected at the growth level of individual neurons, and they become bigger and bigger by extending their branches.

Those branches are called dendrites. They form a system of elaborate arms that extend from neurons cellular bodies, and they can receive stimuli from the external environment.

Han and his team wanted to look at how nutrient deficiency affects the dendrite growth of individual neurons, and then examine what cellular sacrifices bodies make so that vital organs, including the brain, continue to develop.

They divided Drosophila (fruit fly) larva into groups receiving either a high- or low-yeast diet, simulating nutrient-rich and nutrient-poor environments. Then they observed how neural cells developed compared to neighboring skin cells on the body wall. They monitored the progress every 24 hours using confocal microscopy that uses lasers to light up fluorescent markers that label individual cells.

We have very beautiful markers that specifically label these populations of neurons, Han said. Every neuron is very clear to us down to every single branch.

The researchers observed that the neurons grew at a much higher rate than skin cells in the low-yeast environment. Skin cells grew faster when there was less competition for nutrients. Han and his team learned that this difference is due to a critical gene called FoxO an important regulator of cellular stress response.

FoxO is a gene thats expressed in pretty much most cells of the body, Han said. When the cells face low nutrients, FoxO puts a brake on the system and slows cell growth.

Whats particularly interesting about FoxO is that just because most cells have it, doesnt mean they all use it at the same time or under the same conditions. Hans team discovered that even during malnutrition, the Drosophila neurons expressed very little FoxO, whereas the epidermal cells expressed FoxO at much higher levels.

When there are fewer nutrients available, FoxO triggers a response in epidermal cells called autophagy, which tells the cell to self-destruct by consuming itself. However, the limited FoxO expression in neurons preserves individual neural cells and their dendrite growth.

And while humans have more complex systems than Drosophila, Han said that this research helps pave the way for investigating similar phenomenon in humans.

Our study reveals another layer of nervous system sparing under nutrient deficiency and discovers a novel mechanism by which neurons are protected. Han said. These findings may facilitate the development of better approaches to treat problems caused by malnutrition during early development.

Co-authors include Amy Poe, Ph.D. 18; graduate student Yineng Xu; Christine Zhang 19; Joyce Lei 21; Kailyn Li 17; and David Labib 20; they conducted research through theHan Labin the Weill Institute for Cell and Molecular Biology and the Department of Microbiology and Genetics. Poe is currently a postdoctoral researcher at the University of Pennsylvania Perelman School of Medicine; Li is currently in the Doctor of Medicine Program at Weill Cornell Medicine.

This research was supported by a Cornell startup fund and two grants from the National Institutes of Health.

Original post:
Neurons thrive even when malnourished - Newswise

Cell Biology

Prevention of sugar uptake can make cancer cells more sensitive to chemotherapy – News-Medical.Net

By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

The studies, led by researchers at Lund University in Sweden, were carried out on cancer cells in a lab environment. The results were recently published in the research journal Haematologica.

Just like the body's cells, cancer cells need energy like the sugar molecule, glucose. Researchers have long been interested in finding out if it is possible to "starve" cancer cells by preventing sugar uptake.

It is also known that some cancer cells increase their intake of sugar molecules as a survival strategy, which can reduce the effect of treatment. Would it be possible to prevent glucose from entering the cancer cell and in that way increase the effect of chemotherapy?

This is what researchers at Lund University and the University of Pisa have studied.

To enable sugar molecules to enter the cancer cell through the cell membrane, the cell uses so-called sugar transporters, which can be likened to swing doors that let substances in and out.

In total, the researchers can currently identify 14 such sugar transporters. In the present study, the researchers investigated number 1, GLUT1, and its role in acute myeloid leukaemia (AML).

By introducing specially designed inhibitors - substances that prevent or impede activities in the cell membrane - the researchers succeeded in blocking sugar uptake to the cancer cells.

We then examined whether the effect of the chemo used in the treatment of AML was improved when we blocked the sugar uptake. It was clear that the cancer cells became far more sensitive to the chemo drugs"

Karin Lindkvist, Study Lead Author and Professor, Department of Cell Biology, Lund University

The form of cancer the researchers studied, acute myeloid leukaemia, is one of the most common forms of leukaemia among adults.

AML has a relatively poor prognosis and a high risk of relapse, above all among the elderly population, as they often cannot tolerate the tough treatment regime as good as younger patients can.

"Our hope is that combining chemotherapy with inhibitors that block the sugar uptake to the cancer cells, can improve the effect of the treatment and thereby cure more patients in the future", states Anna Hagstrm, Senior Lecturer at the Division of Clinical Genetics, Lund University, and co-author of the study.

Understanding these proteins and how they regulate its swing doors is an important field of research, says Karin Lindkvist.

"Membrane proteins are targets of interest in the development of new treatments and it is commonly known that around half of all drugs on the market today target membrane proteins."

"There is a lot happening in the cell, and these proteins control what goes in and out of the cell."

"This particular sugar transporter appears to play a key role, as it is highly effective at helping the cell to take up sugar. It is also why the cancer cells make more of this transporter in order to obtain more energy", says Karin Lindkvist.

A lot of research remains to be done before it can be used in patients.

"The results need to be repeated both in experimental studies and clinical trials. My hope is that someone will take this further with the aim to treat patients suffering from AML or other cancer diseases that we know use GLUT1 transporters for sugar uptake", she concludes.

Source:

Journal reference:

Abacka, H., et al. (2020) Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance. Haematologica. doi.org/10.3324/haematol.2020.246843.

The rest is here:
Prevention of sugar uptake can make cancer cells more sensitive to chemotherapy - News-Medical.Net

Cell Biology

Live Cell Imaging (LCI) Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast-…

Rising need of live cell imaging going to increasing index of cancer victims is triggering the growth of the market. Its use in drug discovery is growth factor. High cost of imaging equipment is restraining factor for this market. It requires a skilled professional with immense knowledge for imaging and studying the live cells which is restraining factor.

Global live cell imaging market was accounted USD 8.5 billion in 2024. The revenue of this market is anticipated to increase at CAGR of 9% during the forecast period.

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

Browse Full Report: https://www.marketresearchengine.com/reportdetails/live-cell-imaging-market

Live cell imaging associates with research of live cells through microscope. It helps in better understanding of characteristics and behavior of cells. Researchers and scientists use live cell imaging for studying the biological functions.

North America is leading market for live cell imaging industry by revenue which accounted largest share worldwide. Asia Pacific will grow with highest growth rate owing to increase in demand for live cell imaging in healthcare industry and oil and gas industry.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Carl Zeiss AG, Leica Microsystems, Nikon Corporation, Molecular Devices LCC, PerkinElmer Inc., GE Healthcare, Becton, Dickinson and Company, Olympus Corporation, Sigma Aldrich Corporation and Thermo Fisher Scientific Inc. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

This report provides:1) An overview of the global market for live cell imaging and related technologies.

2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024.

3) Identifications of new market opportunities and targeted promotional plans for live cell imaging market.

4) Discussion of research and development, and the demand for new products and new applications.

5) Comprehensive company profiles of major players in the industry.

The global live cell imaging market by product equipment, consumables and software. According to its technology the market is further segmented in to fluorescence recovery after photo bleaching (FRAP), fluorescence resonance energy transfer (FRET), high-content analysis (HCA), ratio metric imaging, fluorescence in situ hybridization (FISH), total internal reflection fluorescence microscopy (TRIF), multi photon excitation microscopy (MPE) and other technologies. The application segment of live cell imaging market consists of cell biology, stem cells, developmental biology and drug discovery. The market segments in terms of geographical regions include North America, Europe, Asia-Pacific and Rest of the World(ROW).

The Live Cell Imaging Market has been segmented as below:

The Live Cell Imaging Market is Segmented on the lines of Product, Technology, Application and Region. By Product this market is segmented on the basis of Equipment its covers Microscopes, Conventional Microscopes, Con focal Microscopes, Advanced Fluorescence Microscopes, Standalone Systems, Cell Analyzers & Image-capturing Devices. Consumables its covers Assay Kits, Reagents, Media & Others. And Software. By Technology this market is segmented on the basis of Fluorescence Recovery After Photo bleaching (FRAP), Fluorescence Resonance Energy Transfer (FRET), High-content Analysis (HCA), Ratio metric Imaging, Fluorescence In Situ Hybridization (FISH), Total Internal Reflection Fluorescence Microscopy (TRIF), Multi photon Excitation Microscopy (MPE) and Other Technologies.

By Application this market is segmented on the basis of Cell Biology, Stem Cells, Developmental Biology and Drug Discovery. By Region this market is segmented on the basis of North America, Europe, Asia Pacific and Rest of the World (RoW).

Reasons to buy this Report:1) Obtains the most up to date information available on all active and planned live cell imaging industry globally.2) Identify growth segments and opportunities in the industry.3) Facilitate decision making on the basis of strong historic and forecast of live cell imaging industry and unit capacity data.4) Assess your competitors refining portfolio and its evolution.

Request Sample Report from here: https://www.marketresearchengine.com/reportdetails/live-cell-imaging-market

Table of Contents

1 INTRODUCTION

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Trends

7 Market Potential Analysis

8 Live Cell Imaging Market, By Product

9 Live Cell Imaging Market, By Technology

10 Live Cell Imaging Market, By Application

11 Live Cell Imaging Market, By Region

12 Competitive Landscape

13 Company Profiles

13.1 Introduction

13.2 Becton, Dickinson and Company

13.3 Carl Zeiss AG

13.4 Danaher Corporation (Leica Microsystems)

13.5 GE Healthcare (Subsidiary of General Electric Company)

13.6 Molecular Devices, LLC

13.7 Nikon Corporation

13.8 Olympus Corporation

13.9 Perkinelmer, Inc.

13.10 Sigma-Aldrich Corporation

13.11 Thermo Fisher Scientific, Inc.

Other Related Market Research Reports:

Liquid Biopsy Market to Perceive Substantial Growth During 2022

Lung Cancer Surgery Market Key Enhancement, Growth Factors Analysis, Product Overview and Share Forecasted to 2022

Intraoperative Imaging Market Growth Factors Analysis, Product Overview and Share Forecasted to 2022

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Follow this link:
Live Cell Imaging (LCI) Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast-...